pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,990 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1184Endpoints903BioPharma Dive348BioSpace317Fierce Biotech301onclive165raps106globenewswire health
therapy area
allOncology7769Rare Disease1891Cardiology1780Immunology1512Hematology1329Vaccines1207Pulmonology
  • Experts discuss managing edema, fatigue and long-term tolerability of antibody-drug conjugates in breast and lung cancer
    The piece concludes a series on antibody-drug conjugates, noting that cumulative toxicities can restrict long-term treatment. Dr. Hope Rugo and Dr. Aaron Lisberg point out that edema and fatigue a…
    onclive · 4mo agoNeutral↗ source
  • Natalie Holles appointed CEO after Third Harmonic shutdown; Mark Alles steps down at ADC Biotech
    Natalie Holles quickly found a new role after the decision to wind down operations at Third Harmonic. She has taken over as chief executive, succeeding Elisabet de los Pinos. At the same time, Mar…
    Endpoints · 4mo agoNeutral↗ source
← prev
page 105 of 120
next →
73
fda recalls70
fda medwatch60
fda press38
1201
Psychiatry & CNS870
Ophthalmology503
Pain483
Endocrinology & Metabolism481
Infectious Disease447
Six former FDA officials explain why they left the agency during the Trump era
STAT's weekly video series STATus Report recently featured a road-trip edition in which reporter Lizzy Lawrence traveled to the Washington suburbs to talk with former FDA staff. The interviews inc…
STAT · 4mo agoNeutral↗ source
  • Spain prepares to isolate over 140 cruise passengers amid hantavirus outbreak
    Spanish authorities are ready to receive more than 140 passengers and crew from a cruise ship flagged with a hantavirus outbreak as it approaches Tenerife. The vessel is expected to dock on Sunday…
    STAT · 4mo agoNegative↗ source
  • OncLive launches weekly quiz covering recent breast, lung and pancreatic cancer updates
    OncLive released its May 8, 2026 weekly news quiz, inviting readers to test their knowledge of recent developments in breast, lung and pancreatic cancers. The quiz highlights several recent oncolo…
    onclive · 4mo agoNeutral↗ source
  • OncLive poll shows oncogene-driven NSCLC as top focus for lung cancer abstracts at ASCO 2026
    OncLive surveyed its LinkedIn and X followers to learn which lung cancer topics will draw the most attention at the 2026 ASCO Annual Meeting in Chicago. The poll asked participants to select the ar…
    onclive · 4mo agoNeutral↗ source
  • Poll Shows Readers Most Excited for PersevERA BC Trial Data at ASCO 2026
    As the 2026 ASCO Annual Meeting draws near, a recent poll asked oncology readers which breast-cancer abstract they are most looking forward to. Respondents could choose among several late-breaking…
    onclive · 4mo agoNeutral↗ source
  • Capricor sues Nippon Shinyaku over pricing dispute for Duchenne cell therapy candidate
    Capricor Therapeutics announced it has filed a lawsuit against its Japanese partner Nippon Shinyaku. The suit alleges a flaw in the pricing terms of the distribution and commercialization agreemen…
    Endpoints · 4mo agoNegative↗ source
  • Calls grow for increased recruitment of men into nursing to address workforce shortages
    Men make up only about 12% of the nursing workforce in the United States. The demand for nurses is rising, with roughly 200,000 job openings expected each year as many current nurses retire. The…
    STAT · 4mo agoPositive↗ source
  • Epidemiologist highlights surge of hantavirus misinformation after cruise ship outbreak
    An outbreak of hantavirus tied to the cruise ship MV Hondius has generated serious health concerns, but online discussion has taken a different turn. Social media users quickly began sharing false…
    STAT · 4mo agoPositive↗ source
  • Immunic appoints Michael Panzara as chief medical officer, coming from Neurvati Neurosciences
    STAT+ columnist Ed Silverman's weekly feature highlights recent personnel changes in pharma. This edition notes a new appointment at Immunic. Immunic has named Michael Panzara its new chief medica…
    STAT · 4mo agoNeutral↗ source
  • Met Gala outfits whimsically matched to biotech logos in annual tradition
    The piece highlights an annual tradition of pairing Met Gala attire with the logos of biotech companies, a playful feature in the STAT newsletter The Readout. For this year’s event, whose theme wa…
    STAT · 4mo agoNeutral↗ source
  • FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer
    The FDA has granted approval for the combination of relacorilant and nab-paclitaxel to treat adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…
    onclive · 4mo agoApprovalPositive↗ source
  • Angelini to acquire Catalyst Pharmaceuticals for $4.1 billion, adding rare CNS drug portfolio
    Angelini Pharma announced it will purchase Catalyst Pharmaceuticals in a cash transaction valued at about $4.1 billion. The agreement pays $31.50 per Catalyst share, representing a 21% premium to…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion, adding three rare-neurology drugs
    Angelini Pharma announced a $4.1 billion acquisition of Catalyst Pharmaceuticals, a U.S. company that develops treatments for rare neurological disorders. The purchase adds three FDA‑approved medi…
    Endpoints · 4mo agoDealPositive↗ source
  • FDA approves small-molecule dasatinib formulation, expanding CML treatment options
    Dr Michael J. Mauro explained that the FDA gave its nod in November 2025 to a generic, small-molecule version of dasatinib, the drug sold as Sprycel, for adult patients with Philadelphia-positive c…
    onclive · 4mo agoApprovalPositive↗ source
  • Sarepta's Elevidys sales beat forecasts but dip again, prompting stock slide and shift to RNA pipeline
    Sarepta Therapeutics reported that its gene therapy Elevidys generated net product revenue that exceeded Wall Street estimates for the first quarter. However, sales continued to decline compared wi…
    BioPharma Dive · 4mo agoEarningsNegative↗ source
  • EnGene shares tumble 80% after Phase 2 bladder cancer data raise safety concerns
    EnGene, a Canadian biotech firm, released updated Phase 2 results for its experimental therapy aimed at a specific group of bladder cancer patients. The company said the new data fell short of expe…
    Endpoints · 4mo agoNegative readoutNegative↗ source
  • Entrada Therapeutics shares plunge after Duchenne trial shows modest dystrophin increase
    Entrada Therapeutics reported early data from a Phase 1/2 study of its RNA‑based therapy ENTR‑601‑44 for Duchenne muscular dystrophy, noting favorable safety and tolerability. The trial showed a d…
    BioPharma Dive · 4mo agoNegative readoutNegative↗ source
  • Political appointee stalls Sanofi drug approval, raising concerns about FDA interference
    STAT's D.C. Diagnosis newsletter reports that a political appointee is impeding the approval of a Sanofi drug, suggesting direct political interference at the FDA. The article notes that the appoi…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 B, Expanding U.S. Rare-Disease Portfolio
    Angelini Pharma announced Thursday it will purchase Catalyst Pharmaceuticals, a Florida‑based company focused on rare‑disease medicines, for about $4.1 billion in cash. The transaction values Cata…
    STAT · 4mo agoDealPositive↗ source
  • Daraxonrasib shows 35% response rate in second‑line RAS‑mutated pancreatic cancer
    Phase 1/2 data from a monotherapy study of daraxonrasib in patients with RAS G12‑mutated pancreatic ductal adenocarcinoma reported an objective response rate of 35% when used as a second‑line treat…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Blackstone invests $250 million in Anagram to address cystic fibrosis complication
    Blackstone Life Sciences announced a $250 million investment in Anagram, a biotech focused on cystic fibrosis complications. The funding is part of one of the largest private investment funds in t…
    Endpoints · 4mo agoDealPositive↗ source
  • FDA holds Type A meeting with Atara after CRL issued for tabelecleucel in EBV-positive PTLD
    The FDA and Atara Biotherapeutics met in a Type A meeting to discuss the complete response letter (CRL) that the agency issued for the biologics license application of tabelecleucel, a therapy for…
    onclive · 4mo agoCRLNegative↗ source
  • Entrada's Duchenne drug shows disappointing early data, shares tumble
    Entrada disclosed initial results from a low‑dose version of its exon‑44 skipping therapy for Duchenne muscular dystrophy. The data, collected from six patients, failed to meet the company’s expect…
    Endpoints · 4mo agoNegative readoutNegative↗ source